Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Jak-2 positive myeloproliferative neoplasms.

Current treatment options in oncology - 1 Jun 2014

Muxí Pablo J, Oliver Ana Carolina

Abstract excerpt

Originally described by Dameshek in 1951, myeloproliferative disorders are today classified as myeloproliferative Neoplasms (MPNs) in WHO's Classification of Tumors of Hematopoietic and Lymphoid Tissues. The term includes a range of conditions, [ie, BCR-ABL-positive chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), primary myelofibrosis (PMF), essential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Share to Myeloproliferative Disorders
Share to Nitriles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Philadelphia Chromosome

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 24627006
DOI: 10.1007/s11864-014-0279-3

Genes

BCR
JAK2
CEL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Jak-2 positive myeloproliferative neoplasms.PMID 24627006Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overviewSemantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Guidelines for the management of myeloproliferative neoplasms.Semantic proximity Read ↗

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.